公开(公告)号：US20090255001A1

公开(公告)日：2009-10-08

申请号：US11911783

申请日：2006-04-18

申请人： Takeo Kato ,  Shigeki Arawaka ,  Hiroto Matsumine

发明人： Takeo Kato ,  Shigeki Arawaka ,  Hiroto Matsumine

IPC分类号： A61K39/395 ,  C12Q1/68 ,  C07H21/04 ,  A61K31/7088 ,  A01K67/027 ,  G01N33/00 ,  A61P25/16

CPC分类号： G01N33/6896 ,  A01K67/0336 ,  A01K2217/05 ,  A01K2227/703 ,  A01K2267/0318 ,  C07K14/723 ,  C12N15/8509 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172 ,  G01N2333/9121 ,  G01N2800/2835

摘要： Large-scale SNP analyses conducted on subjects in a Parkinson's disease patient group and a normal control group led to the successful identification of a gene (GRK5) associated with Parkinson's disease. In addition, it was newly discovered that phosphorylation of α-synuclein is promoted by enhanced expression of the GRK5 gene, and as a result, the formation of soluble α-synuclein oligomers is promoted, leading to Parkinson's disease. The present invention enables the assessment of Parkinson's disease as well as the screening of therapeutic agents for Parkinson's disease using as an index the expression of GRK5 gene.

摘要翻译： 对帕金森病患者组和正常对照组的受试者进行大规模SNP分析，导致与帕金森病相关的基因（GRK5）的成功鉴定。 此外，新发现的是，通过增强GRK5基因的表达来促进α-突触核蛋白的磷酸化，结果促进可溶性α-突触核蛋白寡聚体的形成，导致帕金森病。 本发明能够使用GRK5基因的表达来评估帕金森病以及帕金森病治疗剂的筛选。